Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Brad Hare, MD

    TitleAssociate Clinical Professor
    SchoolUCSF School of Medicine
    DepartmentMedicine
    AddressSFGH Bldg 80
    Phone415-476-4082x556

       Overview 
       Overview
      C. Bradley Hare, MD is Associate Professor of Clinical Medicine and Medical Director, UCSF HIV/AIDS Division at San Francisco General Hospital.

      Research Interests: Dr. Hare conducts patient-based research on a variety of topics important to HIV clinical management, the inspiration for which comes directly from observations in the clinic. Current areas of focus include HIV and Hepatitis C Virus (HCV) co-infection, where he studies the epidemiology, natural history and treatment of acute hepatitis C infection, the use of novel agents in the treatment of HIV-HCV co-infection, and models of HCV treatment in primary care settings. He also conducts research on HIV testing in medical settings such as the Emergency Department, linkage to care after HIV testing, and implementation of a patient-centered medical home for people aging with HIV infection.


       ORNG Applications 
       Websites
       In The News
       Awarded Grants
       Global Health

       Bibliographic 
       Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Christopoulos KA, Massey AD, Lopez AM, Hare CB, Johnson MO, Pilcher CD, Fielding H, Dawson-Rose C. Patient perspectives on the experience of being newly diagnosed with HIV in the emergency department/urgent care clinic of a public hospital. PLoS One. 2013; 8(8):e74199.
        View in: PubMed
      2. Christopoulos KA, Zetola NM, Klausner JD, Haller B, Louie B, Hare CB, Pandori M, Nassos P, Roemer M, Pilcher CD. Leveraging a rapid, round-the-clock HIV testing system to screen for acute HIV infection in a large urban public medical center. J Acquir Immune Defic Syndr. 2013 Feb 1; 62(2):e30-8.
        View in: PubMed
      3. Geng EH, Hare CB, Kahn JO, Jain V, Van Nunnery T, Christopoulos KA, Deeks SG, Gandhi M, Havlir DV. The effect of a "universal antiretroviral therapy" recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater than 500/µL in a public health setting. Clin Infect Dis. 2012 Dec; 55(12):1690-7.
        View in: PubMed
      4. Hoover KW, Butler M, Workowski KA, Follansbee S, Gratzer B, Hare CB, Johnston B, Theodore JL, Tao G, Smith BD, Chorba T, Kent CK. Low rates of hepatitis screening and vaccination of HIV-infected MSM in HIV clinics. Sex Transm Dis. 2012 May; 39(5):349-53.
        View in: PubMed
      5. Clark T, Marquez C, Hare CB, John MD, Klausner JD. Methamphetamine use, transmission risk behavior and internet use among HIV-infected patients in medical care, San Francisco, 2008. AIDS Behav. 2012 Feb; 16(2):396-403.
        View in: PubMed
      6. Hogan CM, Degruttola V, Sun X, Fiscus SA, Del Rio C, Hare CB, Markowitz M, Connick E, Macatangay B, Tashima KT, Kallungal B, Camp R, Morton T, Daar ES, Little S. The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis. 2012 Jan 1; 205(1):87-96.
        View in: PubMed
      7. Geng EH, Kahn JS, Chang OC, Hare CB, Christopoulos KA, Jones D, Petersen ML, Deeks SG, Havlir DV, Gandhi M. The effect of AIDS Clinical Trials Group Protocol 5164 on the time from Pneumocystis jirovecii pneumonia diagnosis to antiretroviral initiation in routine clinical practice: a case study of diffusion, dissemination, and implementation. Clin Infect Dis. 2011 Nov; 53(10):1008-14.
        View in: PubMed
      8. Dowdy DW, Rodriguez RM, Hare CB, Kaplan B. Cost-effectiveness of targeted human immunodeficiency virus screening in an urban emergency department. Acad Emerg Med. 2011 Jul; 18(7):745-53.
        View in: PubMed
      9. Christopoulos KA, Kaplan B, Dowdy D, Haller B, Nassos P, Roemer M, Dowling T, Jones D, Hare CB. Testing and linkage to care outcomes for a clinician-initiated rapid HIV testing program in an urban emergency department. AIDS Patient Care STDS. 2011 Jul; 25(7):439-44.
        View in: PubMed
      10. Yukl SA, Li P, Fujimoto K, Lampiris H, Lu CM, Hare CB, Deeks SG, Liegler T, Pandori M, Havlir DV, Wong JK. Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter. J Virol Methods. 2011 Aug; 175(2):261-5.
        View in: PubMed
      11. Yukl SA, Shergill AK, McQuaid K, Gianella S, Lampiris H, Hare CB, Pandori M, Sinclair E, Günthard HF, Fischer M, Wong JK, Havlir DV. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS. 2010 Oct 23; 24(16):2451-60.
        View in: PubMed
      12. Yukl SA, Gianella S, Sinclair E, Epling L, Li Q, Duan L, Choi AL, Girling V, Ho T, Li P, Fujimoto K, Lampiris H, Hare CB, Pandori M, Haase AT, Günthard HF, Fischer M, Shergill AK, McQuaid K, Havlir DV, Wong JK. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis. 2010 Nov 15; 202(10):1553-61.
        View in: PubMed
      13. Markowitz M, Vaida F, Hare CB, Boden D, Mohri H, Hecht FM, Kalayjian RC, Conrad A, Mildvan D, Aberg J, Hogan C, Kilby JM, Balfour HH, Schafer K, Richman D, Little S. The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection. J Infect Dis. 2010 May 1; 201(9):1298-302.
        View in: PubMed
      14. Tice AD, Bannan M, Bauman K, Collis T, Hall A, Haning W, Hannemann S, Hare CB, Humphry J, Jao R, Leevy C, Lusk H, Ochoa E, Palafox N, Withers N, Akinaka K. Viral hepatitis in Hawai'i--differing perspectives. Hawaii Med J. 2010 Apr; 69(4 Suppl 1):3-20.
        View in: PubMed
      15. Kahn JS, Hilton JF, Van Nunnery T, Leasure S, Bryant KM, Hare CB, Thom DH. Personal health records in a public hospital: experience at the HIV/AIDS clinic at San Francisco General Hospital. J Am Med Inform Assoc. 2010 Mar-Apr; 17(2):224-8.
        View in: PubMed
      16. Marquez C, Mitchell SJ, Hare CB, John M, Klausner JD. Methamphetamine use, sexual activity, patient-provider communication, and medication adherence among HIV-infected patients in care, San Francisco 2004-2006. AIDS Care. 2009 May; 21(5):575-82.
        View in: PubMed
      17. Zetola NM, Bernstein K, Ahrens K, Marcus JL, Philip S, Nieri G, Jones D, Hare CB, Hsu L, Scheer S, Klausner JD. Using surveillance data to monitor entry into care of newly diagnosed HIV-infected persons: San Francisco, 2006-2007. BMC Public Health. 2009; 9:17.
        View in: PubMed
      18. Pilcher CD, Hare CB. The deadliest catch: fishing for HIV in new waters. Ann Intern Med. 2008 Aug 5; 149(3):204-5.
        View in: PubMed
      19. Hare CB, Mellors J, Krambrink A, Su Z, Skiest D, Margolis DM, Patel SS, Barnas D, Frenkel L, Coombs RW, Aweeka F, Morse GD, Haas DW, Boltz V, Palmer S, Coffin J, Havlir DV. Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. Clin Infect Dis. 2008 Aug 1; 47(3):421-4.
        View in: PubMed
      20. Zetola NM, Grijalva CG, Gertler S, Hare CB, Kaplan B, Dowling T, Colfax G, Katz MH, Klausner JD. Simplifying consent for HIV testing is associated with an increase in HIV testing and case detection in highest risk groups, San Francisco January 2003-June 2007. PLoS One. 2008; 3(7):e2591.
        View in: PubMed
      21. Petroll AE, Hare CB, Pinkerton SD. The essentials of HIV: a review for nurses. J Infus Nurs. 2008 Jul-Aug; 31(4):228-35.
        View in: PubMed
      22. Riley ED, Gandhi M, Hare C, Cohen J, Hwang S. Poverty, unstable housing, and HIV infection among women living in the United States. Curr HIV/AIDS Rep. 2007 Dec; 4(4):181-6.
        View in: PubMed
      23. Shoptaw S, Klausner JD, Reback CJ, Tierney S, Stansell J, Hare CB, Gibson S, Siever M, King WD, Kao U, Dang J. A public health response to the methamphetamine epidemic: the implementation of contingency management to treat methamphetamine dependence. BMC Public Health. 2006; 6:214.
        View in: PubMed
      24. Hare CB, Morris JA, Chu A, Gotz V, Loveland JJ, Hodes D, Klaskala W. Comparison of characteristics of treated and non-treated patients with Hepatitis C infection. Pharmacoepidemiol Drug Saf. 2006 Feb; 15(2):71-6.
        View in: PubMed
      25. Hare CB, Pappalardo BL, Busch MP, Karlsson AC, Phelps BH, Alexander SS, Bentsen C, Ramstead CA, Nixon DF, Levy JA, Hecht FM. Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection. Clin Infect Dis. 2006 Mar 1; 42(5):700-8.
        View in: PubMed
      26. Luetkemeyer A, Hare CB, Stansell J, Tien PC, Charlesbois E, Lum P, Havlir D, Peters M. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr. 2006 Jan 1; 41(1):31-6.
        View in: PubMed
      27. Borucki M, Holodniy M, Pierone G, Ruane P, Steinhart C, Williams S, Slom T, Palella F, Hare CB, Yoshidao Y, Li XD, Pollard RB. The safety and tolerability of Z-100 in patients infected with HIV-1. Antivir Ther. 2006; 11(3):297-303.
        View in: PubMed
      28. Hare CB, Loveland JJ, Chu A, Morris JA, Gotz V, Klaskala W. Clinical experience with nonstandard doses ofinterferon alfa-2b and ribavirin in the treatment of chronic hepatitis C infection: A retrospective analysis. Curr Ther Res Clin Exp. 2005 Sep; 66(5):433-50.
        View in: PubMed
      29. Hare CB, Vu MP, Grunfeld C, Lampiris HW. Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death. Clin Infect Dis. 2002 Nov 15; 35(10):e111-2.
        View in: PubMed
      30. Coggins CA, Elion GB, Houghton PJ, Hare CB, Keir S, Colvin OM, Bigner DD, Friedman HS. Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother Pharmacol. 1998; 41(6):485-90.
        View in: PubMed
      31. Hare CB, Elion GB, Colvin OM, Ali-Osman F, Griffith OW, Petros WP, Keir S, Marcelli SL, Bigner DD, Friedman HS. Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft. Cancer Chemother Pharmacol. 1997; 40(5):409-14.
        View in: PubMed
      32. Hare CB, Elion GB, Houghton PJ, Houghton JA, Keir S, Marcelli SL, Bigner DD, Friedman HS. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol. 1997; 39(3):187-91.
        View in: PubMed
      Back to TOP